Peter R. Carroll, MD, MPH

Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer; Taube Family Distinguished Professorship in Urology, UCSF

Associate Director, Strategic Planning and Clinical Services; and Program Leader, Prostate Cancer Program, Helen Diller Family Comprehensive Cancer Center; Associate Dean, School of Medicine; Chair, Department of Urology, UCSF

Cancer Center Program Membership

Prostate Cancer

Research Summary

My main research interests include identifying clinical and pathologic determinants of prostate cancer recurrence, progression, and mortality; discovering novel biomarkers for prostate cancer diagnostics and prognostics; developing evidence-based guidelines for improved management of prostate cancer patients; and examining the impact of lifestyle on health-related quality of life and survivorship among men with prostate cancer. Since 1995, I have been PI of CaPSURE™, a national disease registry study of over 14,000 men with prostate cancer treated at 40+ sites. At UCSF, we have developed a novel program in clinical management of and research on active surveillance for men with low-burden prostate cancer. We are committed to reducing the burden of prostate cancer treatment (physical, psychological and monetary). In 2007, I and colleagues initiated the Prostate Cancer Active Surveillance Study (PASS), a large multi-institutional cohort of men on active surveillance, designed to examine quantitative metabolic, molecular, and physiologic imaging biomarkers and lifestyle factors as novel predictors of prostate cancer progression. We aim to better determine which patients may safely avoid radical treatment, while concurrently identifying men who may benefit from early treatment instead of active surveillance.

Research Funding

  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 30, 2008 - July 31, 2020 - UCSF KURe Career Development Program , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12DK083021
  • September 30, 2009 - August 31, 2012 - Effectiveness of Early Stage Prostate Cancer Treatment , Principal Investigator . Sponsor: NIH, Sponsor Award ID: RC1CA146596
  • September 30, 2006 - August 31, 2012 - Male Reproductive Health Research Career Development Program , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12HD053943


University of California, Berkeley, BA, 1974, Zoology
Georgetown University School of Medicine, Washington, D.C., MD, 1979, Medicine
University of California, Berkeley, MPH, 2008

Honors & Awards

  • Other Experience and Professional Memberships
  • 2002-present
    American Urological Association, Prize Essay Committee (Chair)
  • 2002-2008
    American Urological Association, Update Series Advisory Committee (member)
  • 2001-present
    American Board of Urology, Trustee, President Elect (2006-2008)
  • 2001-present
    American College of Surgeons Commission on Cancer, AUA representative
  • 2000-present
    American Association of Genitourinary Surgeons, Site Committee
  • 2003-present
    American Association of Genitourinary Surgeons, Councilor
  • 2004-present
    ASCO Prostate Cancer Committee, Symposium Committee
  • 2004-present
    ASCO, Oncology Taskforce
  • 2005-present
    ASCO, Cancer Communications Committee, Roster of Cancer Experts
  • 2005-present
    American College of Radiology’s Appropriateness Criteria Expert Panel on Radiation Oncology-Prostate, AUA representative
  • 2006-present
    The Journal of Urology, Associate Editor
  • 2011 – present
    AUA Update, Editor
  • Honors:
  • 2001
    Ken and Donna Derr - Chevron Endowed Chair in Prostate Cancer
  • 2002
    Clinical Society of the American Association of Genitourinary Surgeons
  • 2004
    Ken and Donna Derr-Chevron Distinguished Professorship in Prostate Cancer
  • 2010
    AUA Eugene Fuller Triennial Prostate Award
  • 2010
    Society of Urologic Oncology Medal
  • 2014
    Barringer Medal, American Association of Genitourinary Surgeons

Selected Publications

  1. Langlais CS, Graff RE, Van Blarigan EL, Kenfield SA, Neuhaus J, Tabung FK, Cowan JE, Broering JM, Carroll P, Chan JM. Postdiagnostic Inflammatory, Hyperinsulinemic, and Insulin-Resistant Diets and Lifestyles and the Risk of Prostate Cancer Progression and Mortality. Cancer Epidemiol Biomarkers Prev. 2022 09 02; 31(9):1760-1768.  View on PubMed
  2. Marenghi C, Qiu Z, Helleman J, Nieboer D, Rubio-Briones J, Carroll PR, Lee LS, Valdagni R, Boutros PC, Nicolai N, Movember Foundation’s Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Adverse Pathological Findings at Radical Prostatectomy following Active Surveillance: Results from the Movember GAP3 Cohort. Cancers (Basel). 2022 07 22; 14(15).  View on PubMed
  3. Baskin A, Charondo LB, Balakrishnan A, Cowan JE, Cooperberg MR, Carroll PR, Nguyen H, Shinohara K. Medium Term Outcomes of Focal Cryoablation for Intermediate and High Risk Prostate Cancer: MRI and PSA are Not Predictive of Residual or Recurrent Disease. Urol Oncol. 2022 10; 40(10):451.e15-451.e20.  View on PubMed
  4. Balakrishnan AS, Nguyen HG, Shinohara K, Carroll PR, Odisho AY. Patient engagement in a mobile health intervention to improve preparedness for prostate biopsy. Urol Oncol. 2022 09; 40(9):407.e1-407.e7.  View on PubMed
  5. Filson CP, Zhu K, Huang Y, Zheng Y, Newcomb LF, Williams S, Brooks JD, Carroll PR, Dash A, Ellis WJ, Gleave ME, Liss MA, Martin F, McKenney JK, Morgan TM, Wagner AA, Sokoll LJ, Sanda MG, Chan DW, Lin DW. Impact of Prostate Health Index Results for Prediction of Biopsy Grade Reclassification During Active Surveillance. J Urol. 2022 11; 208(5):1037-1045.  View on PubMed
  6. Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, Sugimoto M, Ehdaie B, Morgan TM, Rubio-Briones J, Semjonow A, Bangma CH, Roobol MJ, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. Eur Urol Open Sci. 2022 Jul; 41:126-133.  View on PubMed
  7. Brady L, Newcomb LF, Zhu K, Zheng Y, Boyer H, Sarkar N, McKenney JK, Brooks JD, Carroll PR, Dash A, Ellis WJ, Filson CP, Gleave ME, Liss MA, Martin F, Morgan TM, Thompson IM, Wagner AA, Pritchard CC, Lin DW, Nelson PS. Germline mutations in penetrant cancer predisposition genes are rare in men with prostate cancer selecting active surveillance. Cancer Med. 2022 11; 11(22):4332-4340.  View on PubMed
  8. Carroll PR. Editorial Comment. J Urol. 2022 07; 208(1):108.  View on PubMed
  9. Greenberg SA, Cowan JE, Lonergan PE, Washington SL, Nguyen HG, Zagoria RJ, Carroll PR. The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. Prostate Cancer Prostatic Dis. 2022 02; 25(2):344-350.  View on PubMed
  10. Shee K, de la Calle CM, Chang AJ, Wong AC, Feng FY, Gottschalk AR, Carroll PR, Nguyen HG. Addition of Enzalutamide to Leuprolide and Definitive Radiation Therapy Is Tolerable and Effective in High-Risk Localized or Regional Nonmetastatic Prostate Cancer: Results From a Phase 2 Trial. Adv Radiat Oncol. 2022 Sep-Oct; 7(5):100941.  View on PubMed
  11. Beckmann KR, Bangma CH, Helleman J, Bjartell A, Carroll PR, Morgan T, Nieboer D, Santaolalla A, Trock BJ, Valdagni R, Roobol MJ, Global Action Plan Active Surveillance Prostate Cancer [G.A.P.3] Consortium. Comparison of outcomes of different biopsy schedules among men on active surveillance for prostate cancer: An analysis of the G.A.P.3 global consortium database. Prostate. 2022 05; 82(7):876-879.  View on PubMed
  12. Ruder S, Gao Y, Ding Y, Bu P, Miles B, De Marzo A, Wheeler T, McKenney JK, Auman H, Fazli L, Simko J, Hurtado-Coll A, Troyer DA, Carroll PR, Gleave M, Platz E, Trock B, Han M, Sayeeduddin M, True LD, Rowley D, Lin DW, Nelson PS, Thompson IM, Feng Z, Wei W, Brooks JD, Ittmann M, Lee M, Ayala G. Development and validation of a quantitative reactive stroma biomarker (qRS) for prostate cancer prognosis. Hum Pathol. 2022 04; 122:84-91.  View on PubMed
  13. Chan E, McKenney JK, Hawley S, Corrigan D, Auman H, Newcomb LF, Boyer HD, Carroll PR, Cooperberg MR, Klein E, Fazli L, Gleave ME, Hurtado-Coll A, Simko JP, Nelson PS, Thompson IM, Tretiakova MS, Troyer D, True LD, Vakar-Lopez F, Lin DW, Brooks JD, Feng Z, Nguyen JK. Analysis of separate training and validation radical prostatectomy cohorts identifies 0.25 mm diameter as an optimal definition for "large" cribriform prostatic adenocarcinoma. Mod Pathol. 2022 08; 35(8):1092-1100.  View on PubMed
  14. Song H, Weinstein HNW, Allegakoen P, Wadsworth MH, Xie J, Yang H, Castro EA, Lu KL, Stohr BA, Feng FY, Carroll PR, Wang B, Cooperberg MR, Shalek AK, Huang FW. Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states. Nat Commun. 2022 01 10; 13(1):141.  View on PubMed
  15. McLachlan AJ, Carroll PR, Hunter DJ, Wakefield TAN, Stosic R. Osteoarthritis management: Does the pharmacist play a role in bridging the gap between what patients actually know and what they ought to know? Insights from a national online survey. Health Expect. 2022 06; 25(3):936-946.  View on PubMed
  16. Chappidi MR, Bell A, Cowan JE, Greenberg SA, Lonergan PE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. J Urol. 2022 05; 207(5):1001-1009.  View on PubMed
  17. Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, Schoots I, Haider M, Moore CM, Denton B, Villers A, Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 Consortium. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. Eur Urol Open Sci. 2022 Jan; 35:59-67.  View on PubMed
  18. Greenland NY, Cooperberg MR, Wong AC, Chan E, Carroll PR, Simko JP, Stohr BA. Molecular risk classifier score and biochemical recurrence risk are associated with cribriform pattern type in Gleason 3+4=7 prostate cancer. Investig Clin Urol. 2022 01; 63(1):27-33.  View on PubMed
  19. Hunter DJ, McLachlan AJ, Carroll PR, Wakefield TAN, Stosic R. Health Literacy and Appropriateness of Self-Care and Pain Management in Osteoarthritis: An Understanding of the Patient's Perspective. Arthritis Care Res (Hoboken). 2021 Dec 23.  View on PubMed
  20. Carroll PR, Hanrahan J. Development and evaluation of an interprofessional student-led influenza vaccination clinic for medical, nursing and pharmacy students. Pharm Pract (Granada). 2021 Oct-Dec; 19(4):2449.  View on PubMed

Go to UCSF Profiles, powered by CTSI